U.K. Secures 30 Million Doses of Coronavirus Vaccine Candidate From Pfizer and BioNTech

If Pfizer's (NYSE: PFE) mRNA-based coronavirus vaccine candidate ends up coming to market, it will find a ready customer in the U.K. government.

The pharmaceutical giant and its partner, Germany-based BioNTech (NASDAQ: BNTX), announced Monday that they signed a deal with the country to supply 30 million doses of the vaccine. This is pending success in clinical trials and approval from the relevant regulators.

Pfizer and BioNTech did not provide the financial details of the arrangement, but did say that its terms depend on timing and volume of doses.

The news comes on the same day that Pfizer and BioNTech released results from an early phase clinical trial of the candidate, BNT162b1, conducted in Germany. These indicate that the vaccine produced potential coronavirus antibodies that effectively prepared immune systems to attack the coronavirus quickly.

Gloved and masked medical researchers using microscopes in a lab.

Image source: Getty Images.

BNT162b1 utilizes messenger RNA (mRNA), the molecule that transmits detailed instructions from DNA to the body's cells on how to make proteins. The concept is that mRNA can form the basis of a vaccine that triggers the body to produce the necessary antibodies to defeat SARS-CoV-2.

In the press release heralding the U.K. deal, BioNTech CEO Ugur Sahin said that the company is working on similar arrangements with other countries. "We are in advanced discussions with multiple other government bodies and hope to announce additional supply agreements soon," he pronounced. 

BNT162b1 is slated to enter phase 2b/3 clinical trials by the end of this month. Pfizer and BioNTech hope to submit it for regulatory review as soon as October.

On their busy Monday, shares of both companies rose, eclipsing the gains of the key stock exchanges. Pfizer was up by 0.7%, while BioNTech climbed 3.5% higher.

10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 2, 2020


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.